A Double-Blind, Placebo-Controlled, Randomized Trial of Montelukast for Acute Bronchiolitis

Abstract

Montelukast did not improve the clinical course in acute bronchiolitis. No significant effect of montelukast on the T-helper 2/T-helper 1 cytokine ratio when given in the early acute phase could be demonstrated.

Acute viral bronchiolitis in South Africa: Strategies for management and prevention

“…A study of montelukast (4 mg daily until discharge) found that it demonstrated no improvement in the clinical course of the disease. [15] In a study of post-bronchiolitis wheeze, montelukast did not improve respiratory symptoms of post-RSV bronchiolitis in children. [16] Similarly, aerosolised ribavirin has been reported not to have any significant consistent beneficial effect in the management of bronchiolitis.…”

Montelukast in the treatment of asthma and beyond

“…The primary outcome was the length of stay, and secondary outcomes included the clinical severity score and changes in type 1 and 2 cytokine levels in nasal lavage. There were neither differences in length of stay nor in clinical severity score or in cytokine levels or types (Th2/Th1) between the two treatment groups [135]. It is possible that montelukast has no effect on healthy infants who experience their first episode of bronchiolitis when it is given after the disease has established.…”

Medicines used in respiratory diseases only seen in children

“…A recent study showed that montelukast does not improve the clinical course of AVB [134]. A preliminary study showed a beneficial effect of montelukast on post-bronchiolitis wheeze [135], but this was not confirmed in a larger study [136].…”